Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma | Zendy

Manish A. Shah | Zendy; YungJue Bang | Zendy; Florian Lordick | Zendy; María Alsina | Zendy; Meng Chen | Zendy; Stephen P. Hack | Zendy; Jean Marie Bruey | Zendy; Dustin Smith | Zendy; Ian McCaffery | Zendy; David S. Shames | Zendy; See Phan | Zendy; David Cunningham | Zendy

Open Access

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma

Author(s) -

Manish A. Shah,

YungJue Bang,

Florian Lordick,

María Alsina,

Meng Chen,

Stephen P. Hack,

Jean Marie Bruey,

Dustin Smith,

Ian McCaffery,

David S. Shames,

See Phan,

David Cunningham

Publication year - 2016

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2016.5580

Subject(s) - medicine , population , oxaliplatin , gastroenterology , clinical endpoint , oncology , progression free survival , placebo , cancer , chemotherapy , randomized controlled trial , pathology , colorectal cancer , alternative medicine , environmental health

Dysregulation of the mesenchymal-epithelial transition (MET) signaling pathway is associated with poor prognosis in gastroesophageal adenocarcinoma (GEC). We report results of METGastric, a phase 3 trial of the MET inhibitor onartuzumab plus standard first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative, MET-positive, advanced GEC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research